Caris Life Sciences, Inc. (CAI) stock
CAINasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/3093% above fair value
$19.94−1.06 (-5.05%)
Close on Nov 17, 2026Market cap $5.63BP/E –Yield –
Caris Life Sciences price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Caris Life Sciences's price to sales ratio was 7.0× on Nov 11, 2026, against 11.1× a year earlier.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 7.0× | −4.7 |
| 2025 | Dec 31, 2025 | 11.7× | – |
See a number that looks wrong?